We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+12.55%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.14B
AUM Growth
+$2.89M
Cap. Flow
-$226M
Cap. Flow %
-10.56%
Top 10 Hldgs %
48.86%
Holding
120
New
11
Increased
17
Reduced
24
Closed
24

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$45.5M
2
SHPG
Shire pic
SHPG
+$33.6M
3
MDRX
Veradigm Inc. Common Stock
MDRX
+$20.4M
4
NPSP
NPS PHARMACEUTICALS INC
NPSP
+$11.6M
5
VTR icon
Ventas
VTR
+$10.8M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$42.4M
2
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$32.8M
3
ILMN icon
Illumina
ILMN
+$22.7M
4
AMGN icon
Amgen
AMGN
+$20.2M
5
IPXL
Impax Laboratories, Inc.
IPXL
+$18.9M

Sector Composition

Rank Sector Weight
1 Healthcare 85.4%
2 Real Estate 4.1%
3 Financials 1.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTR icon
26
Ventas
VTR
$48B
$21M 0.98%
256,389
+136,959
+115% +$10.8M
GEVA
27
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$20.7M 0.97%
223,020
– –
MDRX
28
DELISTED
Veradigm Inc. Common Stock
MDRX
$20.5M 0.96%
+1,604,600
New +$20.4M
ILMN icon
29
Illumina
ILMN
$31B
$19.2M 0.9%
106,749
-129,014
-55% -$22.7M
MOH icon
30
Molina Healthcare
MOH
$10.2B
$18.6M 0.87%
347,901
– –
ENDP
31
DELISTED
Endo International plc
ENDP
$18.2M 0.85%
251,773
-84,442
-25% -$5.78M
IBB icon
32
iShares Biotechnology ETF
IBB
$9.34B
$17.5M 0.82%
173,010
-65,115
-27% -$6.33M
DOC
33
DELISTED
PHYSICIANS REALTY TRUST
DOC
$15.9M 0.74%
958,002
+286,300
+43% +$4.37M
TMO icon
34
Thermo Fisher Scientific
TMO
$213B
$15.2M 0.71%
120,995
-145,880
-55% -$17.7M
OHI icon
35
Omega Healthcare
OHI
$15.1B
$14.7M 0.69%
376,416
+123,800
+49% +$4.69M
MCK icon
36
McKesson
MCK
$100B
$14.1M 0.66%
67,862
– –
MPT
37
Medical Properties Trust
MPT
$2.77B
$13.5M 0.63%
978,774
+351,500
+56% +$4.71M
WELL.PRI
38
DELISTED
Welltower Inc.
WELL.PRI
– –
0
– –
LLY icon
39
Eli Lilly
LLY
$1.02T
$12.9M 0.6%
186,918
– –
MNTA
40
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$12.9M 0.6%
1,067,575
– –
SBRA icon
41
Sabra Healthcare REIT
SBRA
$5.34B
$12.4M 0.58%
407,890
+64,500
+19% +$1.78M
EIGR
42
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$11.8M 0.55%
1,348
-809
-38% -$4.7M
IRWD icon
43
Ironwood Pharmaceuticals
IRWD
$696M
$11.8M 0.55%
917,052
– –
ALR
44
DELISTED
Alere Inc
ALR
$11.3M 0.53%
297,901
– –
ACOR
45
DELISTED
Acorda Therapeutics
ACOR
$11.2M 0.52%
2,276
– –
IPXL
46
DELISTED
Impax Laboratories, Inc.
IPXL
$10.9M 0.51%
344,683
-645,600
-65% -$18.9M
HCA icon
47
HCA Healthcare
HCA
$87.2B
$10.8M 0.51%
147,488
+31,800
+27% +$2.24M
PRGO icon
48
Perrigo
PRGO
$1.4B
$10.5M 0.49%
62,952
– –
VSTM icon
49
Verastem
VSTM
$510M
$10.5M 0.49%
95,819
– –
SGMO
50
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$10.3M 0.48%
679,100
-71,000
-9% -$862K
1
2
3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2014 Portfolio in Review

As of Q4 2014, Tekla Capital Management held 120 positions worth $2.14B, up 0.14% from $2.13B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Tekla Capital Management withdrew a net $226M in Q4 2014, closing 24 positions and reducing 24 holdings. Its most notable exit was CUBIST PHARMACEUTICALS INC, an estimated $32.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 82% a quarter earlier, followed by Real Estate and Financials.

Against the trend, Tekla Capital Management opened a new position in Veradigm Inc. Common Stock worth $20.5M.

  • Tekla Capital Management's largest Q4 2014 buy was Veradigm Inc. Common Stock: 1,604,600 shares worth $20.5M.
  • Tekla Capital Management added most to Biogen in Q4 2014, an estimated $45.5M increase.
  • Tekla Capital Management's biggest Q4 2014 reduction was Gilead Sciences, cutting an estimated $42.4M.
  • Tekla Capital Management fully exited CUBIST PHARMACEUTICALS INC in Q4 2014, selling an estimated $32.8M.
  • Tekla Capital Management's ten largest holdings make up 49% of its $2.14B portfolio in Q4 2014.
  • Tekla Capital Management opened 11 new positions and closed 24 in Q4 2014.
  • Tekla Capital Management's portfolio value rose 0.14% quarter-over-quarter to $2.14B.

Based on Tekla Capital Management's 13F filing for Q4 2014, filed 30 Jan 2015.